shr-4602
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 6, 2023 (NCT05819684)
Timeline
Indications
Studied for
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06704828 | Phase 2 | Dec 31, 2024 | Hengrui Therapeutics, Inc. |
| NCT06560138 | Phase 1 | Nov 15, 2024 | Atridia Pty Ltd. |
| NCT06516926 | Phase 2 | Aug 31, 2024 | Hengrui Therapeutics, Inc. |
| NCT05819684 | Phase 1 | May 6, 2023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2024 |
| Atridia Pty Ltd. | For profit | 1 | 1 | 1 | 2024 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1